Key points from article :
The Cat Health Company (TCHC) has secured funding from Ani.VC, an independent early-stage venture fund, along with Early Game Ventures and several pharmaceutical angels. This investment is part of TCHC's pre-seed funding round, aimed at developing innovative therapeutics for age-related diseases in cats. The company intends to utilize computational and laboratory techniques to address these health concerns, aligning with Ani.VC's mission to support startups that enhance the lives of pets.
Garri Zmudze, co-founder of Ani.VC, expressed confidence in TCHC's potential, noting that their work on novel drugs for feline age-related diseases could significantly improve the quality of life for cats and their owners. TCHC's CEO, Dr. Alex Voda, emphasized the invaluable support from Ani.VC, highlighting their extensive network in the veterinary space, which complements TCHC's existing expertise in pharmaceutical R&D.
Additionally, TCHC is advancing its position in feline health by partnering with EpiPaws to conduct a groundbreaking study on feline longevity. This research will analyse omics data from a cohort of 100 cats, aiming to uncover genetic factors influencing ageing and to develop targeted therapies. With their combined expertise, TCHC and EpiPaws are poised to make transformative strides in feline health. Voda expressed excitement about the future, stating that their goal is not just to extend cats' lives but to enhance the overall quality of those years, paving the way for healthier and happier companions.
